Breast cancers were found to have the highest proportion of ACBD3 gene amplifications, at 8.76%, relative to other cancers such as uterine and prostate (Figure 2), and mutation frequency was low across all the cancers examined. Here, ACBD3 is linked to breast carcinoma.